1	Subjects taking antipsychotics tricyclic antidepressants anxiolytics sedative hypnotics including non-benzodiazepines central opioid agonists/antagonists monoamine oxidase inhibitors MAOIs within at least 5 half lives or for at least 2 weeks whichever is longer prior to randomization|monoamine oxidase inhibitors[154,182]|||||||2 weeks[234,241]|||992698|992698|monoamine oxidase inhibitors
1	Subjects taking antipsychotics tricyclic antidepressants anxiolytics sedative hypnotics including non-benzodiazepines central opioid agonists/antagonists monoamine oxidase inhibitors MAOIs within at least 5 half lives or for at least 2 weeks whichever is longer prior to randomization|agonists[133,141]||||||||||||
1	Subjects taking antipsychotics tricyclic antidepressants anxiolytics sedative hypnotics including non-benzodiazepines central opioid agonists/antagonists monoamine oxidase inhibitors MAOIs within at least 5 half lives or for at least 2 weeks whichever is longer prior to randomization|opioid[126,132]||||||||||71507|71507|opioid
1	Subjects taking antipsychotics tricyclic antidepressants anxiolytics sedative hypnotics including non-benzodiazepines central opioid agonists/antagonists monoamine oxidase inhibitors MAOIs within at least 5 half lives or for at least 2 weeks whichever is longer prior to randomization|benzodiazepines[102,117]||||||||||1402|1402|benzodiazepines
1	Subjects taking antipsychotics tricyclic antidepressants anxiolytics sedative hypnotics including non-benzodiazepines central opioid agonists/antagonists monoamine oxidase inhibitors MAOIs within at least 5 half lives or for at least 2 weeks whichever is longer prior to randomization|hypnotics[78,87]||||||||||5597|5597|hypnotics
1	Subjects taking antipsychotics tricyclic antidepressants anxiolytics sedative hypnotics including non-benzodiazepines central opioid agonists/antagonists monoamine oxidase inhibitors MAOIs within at least 5 half lives or for at least 2 weeks whichever is longer prior to randomization|sedative[69,77]||||||||||9634|9634|sedative
1	Subjects taking antipsychotics tricyclic antidepressants anxiolytics sedative hypnotics including non-benzodiazepines central opioid agonists/antagonists monoamine oxidase inhibitors MAOIs within at least 5 half lives or for at least 2 weeks whichever is longer prior to randomization|anxiolytics[57,68]|||||||||C0040616|10694|10694|anxiolytics
1	Subjects taking antipsychotics tricyclic antidepressants anxiolytics sedative hypnotics including non-benzodiazepines central opioid agonists/antagonists monoamine oxidase inhibitors MAOIs within at least 5 half lives or for at least 2 weeks whichever is longer prior to randomization|tricyclic antidepressants[31,56]|||||||||C0003290|928|928|tricyclic antidepressants
1	Subjects taking antipsychotics tricyclic antidepressants anxiolytics sedative hypnotics including non-benzodiazepines central opioid agonists/antagonists monoamine oxidase inhibitors MAOIs within at least 5 half lives or for at least 2 weeks whichever is longer prior to randomization|antipsychotics[16,30]|||||||||C0040615|10693|10693|antipsychotic drug
